The comparison between the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ) highlights a classic risk-versus-stability dilemma for healthcare investors. XLV offers broad exposure to a diversified portfolio of healthcare assets with a lower expense ratio (0.08%) and higher dividend yield (1.60%) but has had modest returns (26.79% over the past year). In contrast, IBBQ focuses exclusively on biotech and pharmaceutical stocks, boasting a remarkable one-year return of 45.5% despite a significantly higher volatility (max drawdown of 37.94%). While XLV stabilizes returns through major pharmaceutical companies, IBBQ’s success hinges on the high-risk, high-reward nature of biotech innovations. Investors must decide whether they prefer the steadiness of XLV or are willing to embrace the fluctuations associated with IBBQ for potentially higher gains.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/etfs/2026/08/01/xlv-vs-ibbq-is-broad-healthcare-exposure-or-biotech-growth-the-better-etf-buy/
